13th National Forum on

Fraud and Abuse in the Sale and Marketing of Drugs

Reducing Legal Risks and Strengthening Compliance Efforts in the Face of Unprecedented Government Scrutiny

“A total of 74 additional settlements, totaling $10.2 billion in financial penalties, were reached between the federal and state governments and pharmaceutical manufacturers between November 2, 2010 and July 18, 2012, with the first half of 2012 alone already representing a record year for both federal ($5.0 billion) and state ($1.6 billion) financial recoveries.”

 
The government has made it clear that pharmaceutical companies are under a microscope, and the prosecutions will keep coming.  Attend the leading conference which at which to gain the advanced strategies to bulletproof already-robust compliance plans and gain the competitive advantage.

In 2012, federal and state enforcement authorities have aggressively continued their pursuit of pharmaceutical companies for noncompliant sales and marketing practices, resulting in high profile investigations and record-breaking fines: $3 billion awarded against a major company stemming from unlawful promotion and kickbacks… $1.5 billion awarded against a company for unlawful promotion… $1.2 billion awarded against a company for unlawful promotion.  In response to the challenges facing the pharmaceutical industry in this daunting climate, 13th National Forum on Fraud and Abuse in the Sale and Marketing of Drugs provides a forum for the key players - top federal and state prosecutors, preeminent corporate counsel, and leading counsel - to come together to give you a specific action plan to bolster your sales and marketing compliance regime and combat the next wave of fraud and abuse allegations.  

Attendees of this event will:

• Hear directly from multiple panels of current and former prosecutors including 10 current state and federal enforcers who will share inside insights into government enforcement priorities and prepare for how prosecutors will continue to use the most powerful tool in their arsenal, the False Claims Act, in 2013.
• Benchmark best compliance practices against leading companies such as Allergan, Astellas, Eli Lilly and Company, Endo Pharmaceuticals, Ironwood, Johnson & Johnson, LEO Pharma, Medicis, Pfizer, Sandoz, UCB and many more who will share strategies on intensive training, monitoring and supervision of sales and marketing forces.
• Take away cutting-edge knowledge to guard proactively against whistleblowers’ suits and to prevent being on the receiving end of a subpoena stemming from allegations of false claims, anti-kickback violations, and off-label promotion made in the sales and marketing process.
• Gain advanced strategies to implement immediately to meet the massive challenge of aggregate spend compliance in our full-day Advanced Focus on Building a Dynamic Aggregate Spend System in Compliance with Federal Sunshine Mandates, a session designed to prepare you for increasingly aggressive enforcement activity and public scrutiny just in time for the database to go public in early 2013.   
  

Prosecutors are using all the tools at their disposal to ensure that fraud and abuse by device pharmaceutical companies are brought to the light and punished. Do not miss your chance to be part of the most comprehensive forum to formulate innovative solutions for crafting and implementing compliant sales and marketing plans that will withstand scrutiny, boost profits and, most importantly, ensure patient safety. Register today by calling 888-224-2480, fax your form to 877-927-1563, or online at AmericanConference.com/FADrugs

Sponsored by

Media Partners

- click image for pdf -

Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as nontransitional for the purposes of CLE accreditation.

ACI certifies that the activity has been approved for CLE credit by the New York State Continuing Legal Education Board in the amount of 13.5 hours (1.5 hours of ethics credits). An additional 5.5 credit hours will apply to workshop participation.

ACI certifies that this activity has been approved for CLE credit by the State Bar of California in the amount of 11.5 hours (1.25 hours of ethics credits). An additional 4.75 credit hours will apply to workshop participation.You are required to bring your state bar number to complete the appropriate state forms during the conference. CLE credits are processed in 4-8 weeks after a conference is held.

ACI has a dedicated team which processes requests for state approval. Please note that event accreditation varies by state and ACI will make every effort to process your request.Questions about CLE credits for your state? Visit our online CLE Help Center at www.americanconference.com/CLE